CMD 011
Alternative Names: CMD-011Latest Information Update: 13 Jun 2022
At a glance
- Originator Zhejiang Shimai Pharmaceutical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 13 Jun 2022 Preclinical trials in Liver cancer in China, USA (Parenteral) before June 2022 (Zhejiang Shimai Pharmaceutical pipeline, June 2022)
- 13 Jun 2022 Zhejiang Shimai Pharmaceutical intends to submit a IND application for Liver cancer in China and USA in 2022 (Zhejiang Shimai Pharmaceutical pipeline, June 2022)
- 13 Jun 2022 Zhejiang Shimai Pharmaceutical plans to submit NDA in Liver cancer in China in 2025 (Zhejiang Shimai Pharmaceutical pipeline, June 2022)